US · Healthcare · Medical Care Facilities
EPS came in at 0.67 against a street estimate of 0.59 — a beat of 13.6%.
Analysts rate Pediatrix Medical Group, Inc. a hold (1 buy, 6 hold, 0 sell out of 7) with an average price target of $29.17.
CONFIDENT Q2 revenue +4% YoY; adjusted EBITDA $76M solid. Volume down 2% (neonatology pressured) but offset by pricing gains: RCM collections, payer mix, acuity. FY26 EBITDA guidance $280–300M reaffirmed. Aggressive on buybacks (7M shares since Aug 2025) and eyeing M&A in women's/children's care. Q2 2026 No geographic breakdown provided. Company operates across 32 states with 170+ MFMs and presence in 360+ NICUs. Analysts pressed on payer mix resilience vs. peers (subsidy cliff), volume trend sustainability, and pricing driver decomposition. Management attributed payer stability to pregnant population retention incentives, volume decline to seasonality, and quantified RCM as primary pricing engine with expected fade in H2. 2026-08-04…
Full summary in the app.
| Fund | Stake |
|---|---|
| BlackRock Inc | 17.55% |
| Vanguard Portfolio Management, LLC | 7.66% |
| Dimensional Fund Advisors, Inc. | 5.40% |
| Vanguard Capital Management, LLC | 4.63% |
| State Street Corp | 4.52% |
| Victory Capital Management Inc. | 4.37% |
| Wasatch Advisors LP | 3.20% |
| Geode Capital Management, LLC | 2.85% |
| Document | Date |
|---|---|
| Quarterly report · Q3 2026 HEADLINE NUMBERS • Third-quarter 2026 net revenue was $501,374, compared with $492,875 in the third quarter of 2025, an increase of approximately 2%. | 2026-10-29 |
| Results announced · Q4 2026 HEADLINE NUMBERS • Third-quarter 2026 net revenue was $501.4 million, up 1.7% from $492.9 million in the prior-year quarter. • Net income was $47.0 | 2026-10-29 |
| Quarterly report · Q2 2026 PEDIATRIX MEDICAL GROUP, INC. - 10-Q SUMMARY Quarter Ended June 30, 2026 --- HEADLINE NUMBERS • Net Revenue (6 months): $963,979 thousand ($963.98 | 2026-08-04 |
| Results announced · Q3 2026 PEDIATRIX MEDICAL GROUP – Q2 2026 EARNINGS SUMMARY HEADLINE NUMBERS • Q2 2026 EPS: $0.49 per diluted share (GAAP); $0.63 Adjusted EPS (non-GAAP) • Q | 2026-08-04 |
| Board / officer change · Q3 2026 PEDIATRIX MEDICAL GROUP, INC. – 8-K SUMMARY HEADLINE NUMBERS • Company: Pediatrix Medical Group, Inc. (NYSE: MD) • Filing Date: July 24, 2026 • Repor | 2026-07-24 |
| Results announced · Q3 2026 | 2026-07-15 |
| Board / officer change · Q2 2026 PEDIATRIX MEDICAL GROUP, INC. – 8-K SUMMARY HEADLINE NUMBERS • Annual Shareholders' Meeting held May 7, 2026 • 83,072,104 total shares outstanding a | 2026-05-07 |
| Quarterly report · Q1 2026 PEDIATRIX MEDICAL GROUP, INC. – Q1 2026 10-Q SUMMARY --- HEADLINE NUMBERS • Net revenue Q1 2026: $476.2 million (up 3.9% vs. Q1 2025: $458.4 millio | 2026-05-05 |
Readable in the app.
| Announcement | Date |
|---|---|
| Reaffirms full year 2026 Adjusted EBITDA outlook of $280-300 million Pediatrix Medical Group, a physician services company with ~4,300 affiliated clinicians, issued a reassuring Q2 2026 update on July 15, 2026. The company confirmed that despite recent health | 2026-07-15 |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Pediatrix Medical Group, Inc. — free to start.
Open in the appGoogle PlayApp StoreData updated 2026-11-07.